Today, Sphere Fluidics announced the appointment of Richard Hammond as Chief Technical Officer. The company is creating single cell analysis tools that are supported by its unique picodroplet technology.

Richard will be in charge of fostering innovation and expanding Sphere Fluidics’ product line in his capacity as Chief Technical Officer. This will include turning many patented prototypes now under development into finished products. The hiring, which came about as a result of the leadership team’s growth in May 20211, is a sign of the company’s ongoing strategic ambitions to broaden its portfolio of single cell analysis and monoclonality assurance technologies in order to speed up the discovery and development of biotherapeutics.

With over 20 years of expertise leading the development of cutting-edge commercial solutions for healthcare and the life sciences, Richard Hammond, MA MEng, joins Sphere Fluidics. Richard has had a number of significant roles, including product leadership

and technological advancement at DNA Electronics, Cambridge Consultants, and Alere. He has worked in cutting-edge research fields such automated cell transfection, the production of CAR-T cell therapy, and the storing of digital data in DNA. He possesses a wealth of technical knowledge. Richard graduated from King’s College, University of Cambridge, with an engineering MA and MEng.

“Sphere Fluidics has an excellent reputation for providing world-class products for single cell analysis, and I’m delighted to take the opportunity to build on this further,” said Richard Hammond, CTO of Sphere Fluidics. I look forward to working closely with the team to take advantage of the significant potential for expansion into new, emerging application areas and foreign markets, especially with our great new facilities.2”

Sphere Fluidics’ CEO, Dr. Frank F. Craig, continued: “Richard joins us at an exciting time in our international expansion. His expertise will be critical for growth and leadership of our R&D function and design and development of our novel picodroplet-based products. We have an outstanding product portfolio that is continuing to expand to meet customer needs; our systems are designed to simplify and accelerate the study of single cells for pharmaceutical discovery and medical research. All of this will feed into our ambition to become the leader in our field.”